Also worth noting that this was a Phase II drug - not a discovery level peptide that has yet to be proven to have drug-like characteristics, yet alone efficacy in a disease model. The one thing PYC have failed consistently to do is take anything through a proper pre-clinical program, yet alone get into a human. This is the major reason big pharma won't buy them out or do significant deals, as they are so far from being market-ready (8 - 10 years) that there is too much risk, and therefore little value. Tony and Wayne can tyre-pump all they like, but this is reality. Terrible waste of a potentially great platform.
Also worth noting that this was a Phase II drug - not a...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.30 |
Change
0.020(1.56%) |
Mkt cap ! $746.5M | |||
| Open | High | Low | Value | Volume |
| $1.30 | $1.34 | $1.30 | $100.2K | 76.77K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 6502 | $1.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.33 | 20530 | 2 |
View Market Depth
| Last trade - 10.29am 07/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |